← Leaderboards
Jennifer F. Moffat
Upstate Medical University
$2,116,427
Attributed
$2,116,427
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $806.5K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,116,427 · 2
By mechanism
R01$1,309,967 · 1
N01$806,460 · 1
Top collaborators
No co-investigators on record.
Most similar at Upstate Medical University
Same institution · by research overlap
- Steven M Taffet$5,684,982
- Jennifer Moffat$2,958,906
- Gerold Feuer$1,326,895
- Stephen Taffet$846,795
- Heidi Zapata$51,058
Others in their field
Top investigators on “Virus Replication”
- Constance Ann Benson · University Of California, San Diego$187,673,896
- Judith S. Currier · University Of California Los Angeles$137,892,773
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Barton F Haynes · Duke University$110,672,613
- Charles M. Rice · Rockefeller University$53,754,576
- Rama Rao Amara · Emory University$53,347,944
Research focus
Virus ReplicationAntiviral AgentsCell CycleTissue /Cell CultureVaricella Zoster VirusScid MouseCyclin Dependent KinaseDrug Screening /EvaluationCytomegalovirusCell LinePharmacokineticsApoptosisPolymerase Chain ReactionHuman Fetus TissueProtein Structure FunctionFlow CytometryConfocal Scanning MicroscopyClinical ResearchAnimal ModelFluorescence MicroscopyCellsCell ProliferationBlindnessDesign
Grant awards (6)
Task A77: Xenograft mouse models for varicella zoster virus and human cytomegalovirus$806,460
N01 · FY2023 · AI · contact PI
Cdk inhibitors: novel antivirals for VZV$252,217
R01 · FY2007 · AI · contact PI
Cdk inhibitors: novel antivirals for VZV$259,750
R01 · FY2006 · AI · contact PI
Cdk inhibitors: novel antivirals for VZV$266,000
R01 · FY2005 · AI
Cdk inhibitors: novel antivirals for VZV$266,000
R01 · FY2004 · AI
Cdk inhibitors: novel antivirals for VZV$266,000
R01 · FY2003 · AI